Allergios closes their latest round of seed financing

This spring, the seeds are flying for Allergios

Allergios – a biomedical start-up with an innovative allergy test that produces unprecedented accurate results – has just closed their latest round of seed financing. Oversubscribed, this financial contribution will enable them to take their development to the clinical trial stage, now planned for the first half of 2023.

This financial injection is a welcome sign of support for Allergios’ innovation. And, ultimately, it’s a strong sign of support for the millions of allergy sufferers around the world. Allergios’ ingenious technology works by simply visually analyzing how a few drops of blood serum react to an allergen. Armed with only a disposable microfluidic chip and an optical reader, lab assistants get accurate results safely and easily, enabling doctors to provide timely and effective treatment options. This promises to improve the quality of life and increase vitality for those with allergies, while significantly reducing costs.

“The whole team at Allergios wants to thank its investors for their obvious belief in this game-changing technology”, announced Ernst Elhorst, Allergios CEO and co-founder. “We’ve been excited from the very beginning of course, but it’s great to see others understand how revolutionary this technology is and to be able to bring them on-board.”

Visit our website

NLC Health Ventures Footer